Google's AI revolutionizes drug discovery and search experience.

Google Cloud has launched two new AI-powered suites, the Target and Lead Identification Suite and the Multiomics Suite, to help drug companies better understand proteins and amino acids that are key to drug development and to tackle genomic data analysis. The suites aim to speed up drug discovery, lower costs, and create appropriate and even personalized treatments. Early adopters include Pfizer and Cereval for the Target and Lead Identification Suite and Colossal Biosciences for the Multiomics Suite.